GT Biopharma, Inc. (GTBP)
USD 2.3
(-1.29%)
USD 2.3
(-1.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.1 Million USD | -15.7% |
| 2022 | 16.73 Million USD | -47.97% |
| 2021 | 32.16 Million USD | 468.26% |
| 2020 | 5.66 Million USD | 1329.55% |
| 2019 | 396 Thousand USD | -98.44% |
| 2018 | 25.39 Million USD | -90.01% |
| 2017 | 254.36 Million USD | 1017372.0% |
| 2016 | 25 Thousand USD | -53.7% |
| 2015 | 54 Thousand USD | -93.92% |
| 2014 | 888 Thousand USD | 504.08% |
| 2013 | 147 Thousand USD | -34.96% |
| 2012 | 226 Thousand USD | 75.19% |
| 2011 | 129 Thousand USD | -30.27% |
| 2010 | 185 Thousand USD | -86.63% |
| 2009 | 1.38 Million USD | 134.58% |
| 2008 | 590 Thousand USD | -87.85% |
| 2007 | 4.85 Million USD | -39.26% |
| 2006 | 7.99 Million USD | 2.45% |
| 2005 | 7.8 Million USD | -9.19% |
| 2004 | 8.59 Million USD | 337.9% |
| 2003 | 1.96 Million USD | -1.11% |
| 2002 | 1.98 Million USD | 15.34% |
| 2001 | 1.72 Million USD | -69.4% |
| 2000 | 5.62 Million USD | 8.51% |
| 1999 | 5.18 Million USD | -53.71% |
| 1998 | 11.2 Million USD | -11.11% |
| 1997 | 12.6 Million USD | 57.5% |
| 1996 | 8 Million USD | -19.19% |
| 1995 | 9.9 Million USD | -11.61% |
| 1994 | 11.2 Million USD | 261.29% |
| 1993 | 3.1 Million USD | -36.73% |
| 1992 | 4.9 Million USD | 2.08% |
| 1991 | 4.8 Million USD | -4.0% |
| 1990 | 5 Million USD | 13.64% |
| 1989 | 4.4 Million USD | 25.71% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 9.26 Million USD | -6.51% |
| 2024 Q1 | 9.91 Million USD | -29.75% |
| 2023 Q4 | 14.1 Million USD | -12.63% |
| 2023 Q2 | 18.14 Million USD | -9.67% |
| 2023 Q1 | 20.08 Million USD | 20.02% |
| 2023 Q3 | 16.14 Million USD | -11.0% |
| 2023 FY | 14.1 Million USD | -15.7% |
| 2022 Q1 | 27.43 Million USD | -14.7% |
| 2022 Q3 | 21.07 Million USD | -12.82% |
| 2022 Q2 | 24.17 Million USD | -11.91% |
| 2022 Q4 | 16.73 Million USD | -20.57% |
| 2022 FY | 16.73 Million USD | -47.97% |
| 2021 Q4 | 32.16 Million USD | -10.14% |
| 2021 FY | 32.16 Million USD | 468.26% |
| 2021 Q2 | 39.56 Million USD | 43.14% |
| 2021 Q1 | 27.64 Million USD | 388.31% |
| 2021 Q3 | 35.79 Million USD | -9.53% |
| 2020 Q2 | 1.06 Million USD | 260.34% |
| 2020 Q1 | 295 Thousand USD | -25.51% |
| 2020 Q3 | 917 Thousand USD | -13.73% |
| 2020 Q4 | 5.66 Million USD | 517.34% |
| 2020 FY | 5.66 Million USD | 1329.55% |
| 2019 Q4 | 396 Thousand USD | -17.84% |
| 2019 Q1 | 25.53 Million USD | 0.55% |
| 2019 FY | 396 Thousand USD | -98.44% |
| 2019 Q2 | 25.7 Million USD | 0.66% |
| 2019 Q3 | 482 Thousand USD | -98.13% |
| 2018 Q4 | 25.39 Million USD | -4.28% |
| 2018 Q3 | 26.53 Million USD | -89.59% |
| 2018 Q2 | 255.01 Million USD | -0.9% |
| 2018 Q1 | 257.33 Million USD | 1.17% |
| 2018 FY | 25.39 Million USD | -90.01% |
| 2017 FY | 254.36 Million USD | 1017372.0% |
| 2017 Q1 | 238 Thousand USD | 852.0% |
| 2017 Q3 | 256.52 Million USD | 610661.9% |
| 2017 Q2 | 42 Thousand USD | -82.35% |
| 2017 Q4 | 254.36 Million USD | -0.84% |
| 2016 FY | 25 Thousand USD | -53.7% |
| 2016 Q3 | 160 Thousand USD | -55.8% |
| 2016 Q2 | 362 Thousand USD | 878.38% |
| 2016 Q1 | 37 Thousand USD | -31.48% |
| 2016 Q4 | 25 Thousand USD | -84.38% |
| 2015 Q4 | 54 Thousand USD | 10.2% |
| 2015 FY | 54 Thousand USD | -93.92% |
| 2015 Q1 | 1.42 Million USD | 60.47% |
| 2015 Q2 | 132 Thousand USD | -90.74% |
| 2015 Q3 | 49 Thousand USD | -62.88% |
| 2014 Q2 | 52 Thousand USD | -49.51% |
| 2014 Q1 | 103 Thousand USD | -29.93% |
| 2014 Q4 | 888 Thousand USD | 25.07% |
| 2014 Q3 | 710 Thousand USD | 1265.38% |
| 2014 FY | 888 Thousand USD | 504.08% |
| 2013 Q3 | 62 Thousand USD | -59.74% |
| 2013 Q1 | 118 Thousand USD | -47.79% |
| 2013 Q2 | 154 Thousand USD | 30.51% |
| 2013 Q4 | 147 Thousand USD | 137.1% |
| 2013 FY | 147 Thousand USD | -34.96% |
| 2012 Q3 | 88 Thousand USD | -29.6% |
| 2012 Q4 | 226 Thousand USD | 156.82% |
| 2012 FY | 226 Thousand USD | 75.19% |
| 2012 Q1 | 166 Thousand USD | 28.68% |
| 2012 Q2 | 125 Thousand USD | -24.7% |
| 2011 FY | 129 Thousand USD | -30.27% |
| 2011 Q1 | 137 Thousand USD | -25.95% |
| 2011 Q2 | 228 Thousand USD | 66.42% |
| 2011 Q3 | 371 Thousand USD | 62.72% |
| 2011 Q4 | 129 Thousand USD | -65.23% |
| 2010 FY | 185 Thousand USD | -86.63% |
| 2010 Q4 | 185 Thousand USD | -43.77% |
| 2010 Q3 | 329 Thousand USD | -52.11% |
| 2010 Q2 | 687 Thousand USD | -25.65% |
| 2010 Q1 | 924 Thousand USD | -33.24% |
| 2009 Q1 | 558 Thousand USD | -5.42% |
| 2009 FY | 1.38 Million USD | 134.58% |
| 2009 Q4 | 1.38 Million USD | 134.97% |
| 2009 Q3 | 589 Thousand USD | -8.26% |
| 2009 Q2 | 642 Thousand USD | 15.05% |
| 2008 Q1 | 4.76 Million USD | -2.0% |
| 2008 FY | 590 Thousand USD | -87.85% |
| 2008 Q4 | 590 Thousand USD | -29.85% |
| 2008 Q3 | 841 Thousand USD | -39.37% |
| 2008 Q2 | 1.38 Million USD | -70.86% |
| 2007 Q1 | 4.88 Million USD | -38.93% |
| 2007 FY | 4.85 Million USD | -39.26% |
| 2007 Q3 | 5.53 Million USD | 6.13% |
| 2007 Q2 | 5.21 Million USD | 6.82% |
| 2007 Q4 | 4.85 Million USD | -12.28% |
| 2006 Q4 | 7.99 Million USD | 4.84% |
| 2006 FY | 7.99 Million USD | 2.45% |
| 2006 Q2 | 7.58 Million USD | -4.35% |
| 2006 Q1 | 7.92 Million USD | 1.54% |
| 2006 Q3 | 7.62 Million USD | 0.62% |
| 2005 FY | 7.8 Million USD | -9.19% |
| 2005 Q4 | 7.8 Million USD | 36.92% |
| 2005 Q1 | 6.69 Million USD | -22.11% |
| 2005 Q2 | 6.2 Million USD | -7.33% |
| 2005 Q3 | 5.7 Million USD | -8.11% |
| 2004 Q3 | 2.66 Million USD | -3.48% |
| 2004 FY | 8.59 Million USD | 337.9% |
| 2004 Q1 | 1.96 Million USD | 0.25% |
| 2004 Q4 | 8.59 Million USD | 222.92% |
| 2004 Q2 | 2.75 Million USD | 40.14% |
| 2003 Q2 | 1.88 Million USD | -1.77% |
| 2003 Q1 | 1.92 Million USD | -3.22% |
| 2003 FY | 1.96 Million USD | -1.11% |
| 2003 Q3 | 1.93 Million USD | 2.7% |
| 2003 Q4 | 1.96 Million USD | 1.29% |
| 2002 Q1 | 2.89 Million USD | 68.45% |
| 2002 FY | 1.98 Million USD | 15.34% |
| 2002 Q4 | 1.98 Million USD | -4.89% |
| 2002 Q3 | 2.08 Million USD | -19.36% |
| 2002 Q2 | 2.58 Million USD | -10.73% |
| 2001 Q1 | 4.29 Million USD | -23.64% |
| 2001 FY | 1.72 Million USD | -69.4% |
| 2001 Q4 | 1.72 Million USD | -8.85% |
| 2001 Q3 | 1.88 Million USD | -27.77% |
| 2001 Q2 | 2.61 Million USD | -39.14% |
| 2000 Q3 | 7.1 Million USD | -14.76% |
| 2000 Q4 | 5.62 Million USD | -20.85% |
| 2000 Q2 | 8.33 Million USD | 2.21% |
| 2000 FY | 5.62 Million USD | 8.51% |
| 2000 Q1 | 8.15 Million USD | 57.37% |
| 1999 Q3 | 5.2 Million USD | -17.46% |
| 1999 Q2 | 6.3 Million USD | -23.17% |
| 1999 Q1 | 8.2 Million USD | -26.79% |
| 1999 Q4 | 5.18 Million USD | -0.31% |
| 1999 FY | 5.18 Million USD | -53.71% |
| 1998 Q4 | 11.2 Million USD | -16.42% |
| 1998 FY | 11.2 Million USD | -11.11% |
| 1998 Q3 | 13.4 Million USD | 1.52% |
| 1998 Q1 | 10.5 Million USD | -16.67% |
| 1998 Q2 | 13.2 Million USD | 25.71% |
| 1997 Q4 | 12.6 Million USD | 32.63% |
| 1997 Q3 | 9.5 Million USD | -9.52% |
| 1997 Q2 | 10.5 Million USD | 40.0% |
| 1997 Q1 | 7.5 Million USD | -6.25% |
| 1997 FY | 12.6 Million USD | 57.5% |
| 1996 FY | 8 Million USD | -19.19% |
| 1996 Q2 | 8.9 Million USD | -6.32% |
| 1996 Q4 | 8 Million USD | 0.0% |
| 1996 Q3 | 8 Million USD | -10.11% |
| 1996 Q1 | 9.5 Million USD | -4.04% |
| 1995 Q1 | 11.1 Million USD | -0.89% |
| 1995 FY | 9.9 Million USD | -11.61% |
| 1995 Q3 | 10.3 Million USD | -2.83% |
| 1995 Q4 | 9.9 Million USD | -3.88% |
| 1995 Q2 | 10.6 Million USD | -4.5% |
| 1994 FY | 11.2 Million USD | 261.29% |
| 1994 Q2 | 3.7 Million USD | 19.35% |
| 1994 Q1 | 3.1 Million USD | 0.0% |
| 1994 Q4 | 11.2 Million USD | -7.44% |
| 1994 Q3 | 12.1 Million USD | 227.03% |
| 1993 Q4 | 3.1 Million USD | -11.43% |
| 1993 FY | 3.1 Million USD | -36.73% |
| 1993 Q2 | 3.5 Million USD | -28.57% |
| 1993 Q1 | 4.9 Million USD | 0.0% |
| 1993 Q3 | 3.5 Million USD | 0.0% |
| 1992 Q4 | 4.9 Million USD | 2.08% |
| 1992 Q2 | 4.8 Million USD | 6.67% |
| 1992 Q1 | 4.5 Million USD | -6.25% |
| 1992 FY | 4.9 Million USD | 2.08% |
| 1992 Q3 | 4.8 Million USD | 0.0% |
| 1991 Q3 | 5.3 Million USD | 6.0% |
| 1991 Q2 | 5 Million USD | 2.04% |
| 1991 Q1 | 4.9 Million USD | -2.0% |
| 1991 Q4 | 4.8 Million USD | -9.43% |
| 1991 FY | 4.8 Million USD | -4.0% |
| 1990 Q4 | 5 Million USD | 4.17% |
| 1990 Q3 | 4.8 Million USD | -5.88% |
| 1990 Q2 | 5.1 Million USD | 4.08% |
| 1990 Q1 | 4.9 Million USD | 11.36% |
| 1990 FY | 5 Million USD | 13.64% |
| 1989 Q2 | 4.2 Million USD | 0.0% |
| 1989 Q4 | 4.4 Million USD | 2.33% |
| 1989 Q3 | 4.3 Million USD | 2.38% |
| 1989 FY | 4.4 Million USD | 25.71% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.052% |
| Alkermes plc | 2.13 Billion USD | 99.34% |
| Agenus Inc. | 313.91 Million USD | 95.505% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.632% |
| Aptorum Group Limited | 20.64 Million USD | 31.643% |
| Ardelyx, Inc. | 297.57 Million USD | 95.259% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 98.157% |
| Bicycle Therapeutics plc | 595.34 Million USD | 97.63% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 80.857% |
| ChromaDex Corporation | 54.96 Million USD | 74.33% |
| Chimerix, Inc. | 212.77 Million USD | 93.369% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 50.096% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 96.8% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.367% |
| Precision BioSciences, Inc. | 159.78 Million USD | 91.17% |
| Dyadic International, Inc. | 8.21 Million USD | -71.658% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 55.548% |
| Fortress Biotech, Inc. | 167.52 Million USD | 91.578% |
| Lantern Pharma Inc. | 43.64 Million USD | 67.675% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 91.255% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 2.741% |
| Incyte Corporation | 6.78 Billion USD | 99.792% |
| IO Biotech, Inc. | 150.71 Million USD | 90.639% |
| Jaguar Health, Inc. | 50.76 Million USD | 72.206% |
| Novavax, Inc. | 1.85 Billion USD | 99.24% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 96.291% |
| Opthea Limited | 188.79 Million USD | 92.527% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 98.306% |
| ContextLogic Inc. | 423 Million USD | 96.665% |
| MiMedx Group, Inc. | 239.04 Million USD | 94.098% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 91.879% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -172.917% |
| NextCure, Inc. | 129.41 Million USD | 89.098% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 73.847% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 61.586% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 56.32% |
| Vaxcyte, Inc. | 1.4 Billion USD | 98.998% |
| PDS Biotechnology Corporation | 59.39 Million USD | 76.244% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 97.797% |
| Pharming Group N.V. | 462.85 Million USD | 96.952% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 63.524% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 97.755% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 25.443% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 25.443% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 91.466% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 68.845% |
| Acelyrin, Inc. | 742.69 Million USD | 98.1% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -114.21% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -120.35% |
| Summit Therapeutics Inc. | 202.94 Million USD | 93.048% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 81.03% |
| Senti Biosciences, Inc. | 119.48 Million USD | 88.192% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 93.821% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 91.61% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -70.749% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -195.553% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 96.993% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 88.59% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 94.869% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 97.016% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -39.624% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 93.423% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -1146.203% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 96.591% |
| Immix Biopharma, Inc. | 19.92 Million USD | 29.19% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 96.187% |
| MEI Pharma, Inc. | 41.37 Million USD | 65.9% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 56.462% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 95.86% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 87.964% |
| Fortress Biotech, Inc. | 167.52 Million USD | 91.578% |
| Precigen, Inc. | 151.04 Million USD | 90.659% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 58.525% |
| AlloVir, Inc. | 190.79 Million USD | 92.605% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 96.252% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 97.213% |
| ImmuCell Corporation | 43.8 Million USD | 67.794% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 97.827% |
| Onconetix, Inc. | 88.82 Million USD | 84.115% |
| PureTech Health plc | 693.97 Million USD | 97.967% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 85.557% |
| Elevation Oncology, Inc. | 89.09 Million USD | 84.163% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -127.491% |
| Seer, Inc. | 436.26 Million USD | 96.766% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 82.709% |
| Innoviva, Inc. | 1.24 Billion USD | 98.865% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 89.346% |
| ESSA Pharma Inc. | 149.12 Million USD | 90.539% |
| GlycoMimetics, Inc. | 45.31 Million USD | 68.866% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 95.418% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 94.163% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 97.01% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 72.17% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 85.181% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -2133.893% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 97.509% |
| Aptose Biosciences Inc. | 12.92 Million USD | -9.181% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 36.2% |
| Soligenix, Inc. | 9.79 Million USD | -44.009% |
| Century Therapeutics, Inc. | 360.69 Million USD | 96.088% |
| Kura Oncology, Inc. | 448.93 Million USD | 96.857% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 94.816% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 18.422% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 87.279% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 93.123% |
| Autolus Therapeutics plc | 375.38 Million USD | 96.241% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 94.393% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 96.028% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 71.283% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 97.866% |
| GRI Bio, Inc. | 2.95 Million USD | -377.3% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -33.038% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 91.726% |
| IGM Biosciences, Inc. | 423.41 Million USD | 96.668% |
| INmune Bio, Inc. | 57 Million USD | 75.248% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 93.659% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 83.192% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 45.977% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -104.977% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 81.245% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 90.419% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 91.475% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 97.759% |
| Verastem, Inc. | 149.71 Million USD | 90.576% |
| Abeona Therapeutics Inc. | 64 Million USD | 77.955% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 97.245% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 90.865% |
| Histogen Inc. | 19.07 Million USD | 26.026% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 37.709% |
| Surrozen, Inc. | 46.08 Million USD | 69.382% |
| Organovo Holdings, Inc. | 6.34 Million USD | -122.224% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -227.46% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 90.204% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -19.548% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 81.255% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -65.613% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 96.113% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 22.026% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 96.714% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -11.872% |
| Apollomics, Inc. | 55.38 Million USD | 74.527% |
| Amarin Corporation plc | 831.68 Million USD | 98.304% |
| Mesoblast Limited | 669.15 Million USD | 97.892% |
| Turnstone Biologics Corp. | 112.81 Million USD | 87.494% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 97.549% |
| Synaptogenix, Inc. | 31.11 Million USD | 54.653% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -15.799% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 97.426% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -140.265% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -92.086% |
| Exelixis, Inc. | 2.94 Billion USD | 99.52% |
| Better Therapeutics, Inc. | 22.94 Million USD | 38.504% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 96.13% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 98.211% |
| NLS Pharmaceutics AG | 1.84 Million USD | -664.036% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -76.835% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 3.988% |
| Gritstone bio, Inc. | 177.76 Million USD | 92.063% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 85.208% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 21.012% |
| Avid Bioservices, Inc. | 336.55 Million USD | 95.808% |
| Insmed Incorporated | 1.32 Billion USD | 98.939% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -46.536% |
| MediWound Ltd. | 66.45 Million USD | 78.77% |
| OmniAb, Inc. | 401.98 Million USD | 96.49% |
| Alector, Inc. | 621.82 Million USD | 97.731% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 96.066% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -162.347% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 75.113% |
| Zai Lab Limited | 1.03 Billion USD | 98.639% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 97.051% |
| Aura Biosciences, Inc. | 255.07 Million USD | 94.469% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 98.119% |
| Immunic, Inc. | 54.29 Million USD | 74.016% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 94.7% |
| Veracyte, Inc. | 1.13 Billion USD | 98.76% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -19.337% |
| FibroGen, Inc. | 423.52 Million USD | 96.669% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -301.623% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -197.872% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -159.859% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.876% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -60.239% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 97.273% |
| TG Therapeutics, Inc. | 329.58 Million USD | 95.719% |
| Galecto, Inc. | 38.22 Million USD | 63.092% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 50.799% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.676% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 94.006% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 43.205% |
| XBiotech Inc. | 227.24 Million USD | 93.791% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 85.208% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 90.106% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 95.065% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 88.966% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 96.307% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.054% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 96.133% |
| Vaxxinity, Inc. | 44.35 Million USD | 68.189% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 97.271% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 24.183% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 95.375% |
| NexImmune, Inc. | 8.59 Million USD | -64.174% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -31.673% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 17.623% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.957% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 36.306% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -3496.803% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 91.86% |
| Ainos, Inc. | 31.84 Million USD | 55.69% |
| Pluri Inc. | 39.52 Million USD | 64.305% |
| Prothena Corporation plc | 696.38 Million USD | 97.974% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 95.008% |
| Celularity Inc. | 143.88 Million USD | 90.195% |
| Rallybio Corporation | 115.62 Million USD | 87.797% |
| Cue Biopharma, Inc. | 61.53 Million USD | 77.07% |
| MeiraGTx Holdings plc | 458.16 Million USD | 96.921% |
| Omeros Corporation | 378.26 Million USD | 96.27% |
| Humacyte, Inc. | 128.22 Million USD | 88.997% |
| Immunocore Holdings plc | 597 Million USD | 97.637% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 54.864% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 79.412% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 98.655% |
| CalciMedica, Inc. | 12.18 Million USD | -15.79% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 94.438% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 91.745% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 95.464% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 97.504% |
| Pulmatrix, Inc. | 33.95 Million USD | 58.452% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 48.025% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 89.984% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 98.916% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 89.163% |
| Cytokinetics, Incorporated | 824.31 Million USD | 98.288% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 33.206% |
| Nutriband Inc. | 7.51 Million USD | -87.691% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 82.13% |
| Vor Biopharma Inc. | 209.82 Million USD | 93.276% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.805% |
| Evogene Ltd. | 51.1 Million USD | 72.39% |
| ProKidney Corp. | 420.55 Million USD | 96.645% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 74.269% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -48.199% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 97.418% |
| CorMedix Inc. | 82.05 Million USD | 82.806% |
| BioLineRx Ltd. | 63.92 Million USD | 77.929% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 96.495% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 49.968% |
| Atai Life Sciences N.V. | 293.47 Million USD | 95.192% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 91.351% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 88.927% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 97.49% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 85.412% |
| MediciNova, Inc. | 66.26 Million USD | 78.71% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 83.958% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -216.178% |
| GeoVax Labs, Inc. | 9.28 Million USD | -51.984% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 97.601% |
| Biomea Fusion, Inc. | 199.92 Million USD | 92.943% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.259% |
| Mereo BioPharma Group plc | 66.49 Million USD | 78.783% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 97.092% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 97.698% |
| Absci Corporation | 234.48 Million USD | 93.983% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -92.878% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 95.849% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 91.453% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 97.319% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 94.919% |
| Allakos Inc. | 243.61 Million USD | 94.208% |
| Imunon, Inc. | 21.91 Million USD | 35.628% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 94.525% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 97.73% |
| BioAtla, Inc. | 119.65 Million USD | 88.209% |
| NLS Pharmaceutics AG | 1.84 Million USD | -664.036% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -338.168% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 97.805% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 85.293% |
| XOMA Corporation | 234.3 Million USD | 93.978% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 93.623% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 88.789% |
| aTyr Pharma, Inc. | 122.06 Million USD | 88.442% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 90.833% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 97.569% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 97.123% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 87.228% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 6.918% |
| Akari Therapeutics, Plc | 4.35 Million USD | -223.972% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 17.188% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.186% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -357.492% |
| UroGen Pharma Ltd. | 178.31 Million USD | 92.087% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 97.003% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -2438.891% |
| Orgenesis Inc. | 14.55 Million USD | 3.044% |
| Entera Bio Ltd. | 11.76 Million USD | -19.924% |
| GH Research PLC | 226.3 Million USD | 93.765% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 74.204% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 86.868% |
| Xencor, Inc. | 952.69 Million USD | 98.519% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -81.262% |
| Replimune Group, Inc. | 487.72 Million USD | 97.107% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -74.809% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 97.824% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -357.492% |
| Portage Biotech Inc. | 7.77 Million USD | -81.373% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -216.178% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 94.905% |
| OncoCyte Corporation | 74.89 Million USD | 81.161% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -593.914% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -143.82% |
| Purple Biotech Ltd. | 44.3 Million USD | 68.153% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 58.656% |
| scPharmaceuticals Inc. | 94.47 Million USD | 85.067% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 21.812% |
| HilleVax, Inc. | 344.43 Million USD | 95.904% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -344.238% |
| Tharimmune, Inc. | 10.94 Million USD | -28.892% |
| Genprex, Inc. | 10.67 Million USD | -32.223% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 97.157% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 85.342% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -481.575% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -238.716% |
| OKYO Pharma Limited | 1.54 Million USD | -815.417% |
| Savara Inc. | 177.56 Million USD | 92.054% |
| Curis, Inc. | 77.28 Million USD | 81.743% |
| Daré Bioscience, Inc. | 21.28 Million USD | 33.705% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 77.937% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -74.487% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 27.164% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.757% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -15.942% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.324% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 96.058% |
| Erasca, Inc. | 395.29 Million USD | 96.431% |
| bluebird bio, Inc. | 619.16 Million USD | 97.721% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -226.343% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.794% |
| DBV Technologies S.A. | 182.98 Million USD | 92.29% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -226.343% |
| Moderna, Inc. | 18.42 Billion USD | 99.923% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 22.55% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -21.776% |
| Molecular Templates, Inc. | 35.38 Million USD | 60.125% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 89.796% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 98.212% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 95.355% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 86.427% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 96.97% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 95.499% |
| MacroGenics, Inc. | 306.82 Million USD | 95.402% |
| RenovoRx, Inc. | 1.46 Million USD | -862.415% |
| Adicet Bio, Inc. | 207.29 Million USD | 93.194% |
| Prime Medicine, Inc. | 193.85 Million USD | 92.722% |
| Aditxt, Inc. | 44.57 Million USD | 68.35% |
| Adagene Inc. | 115.72 Million USD | 87.809% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -216.758% |
| Quantum-Si incorporated | 298.25 Million USD | 95.269% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.051% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -83.017% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 95.984% |
| SciSparc Ltd. | 11.18 Million USD | -26.176% |
| Vericel Corporation | 353.65 Million USD | 96.011% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -15.528% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 75.204% |
| Generation Bio Co. | 374.75 Million USD | 96.235% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 94.46% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 91.102% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 95.867% |
| Invivyd, Inc. | 229.18 Million USD | 93.844% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 98.328% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -15.939% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 92.264% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 30.92% |
| 2seventy bio, Inc. | 565.42 Million USD | 97.505% |
| ADMA Biologics, Inc. | 329.18 Million USD | 95.714% |
| Clene Inc. | 52.34 Million USD | 73.044% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 75.978% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 89.138% |
| GeoVax Labs, Inc. | 9.28 Million USD | -51.984% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 97.842% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 86.383% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 89.179% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 85.537% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 80.127% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 94.183% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.28% |
| Evaxion Biotech A/S | 12.88 Million USD | -9.469% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 94.403% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 98.126% |
| Trevena, Inc. | 40.6 Million USD | 65.253% |
| Surrozen, Inc. | 46.08 Million USD | 69.382% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 93.753% |
| Cingulate Inc. | 3.49 Million USD | -304.103% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 15.154% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 78.522% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -20.748% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 94.746% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 98.116% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 88.793% |
| Clearmind Medicine Inc. | 4.32 Million USD | -226.266% |
| Kronos Bio, Inc. | 213.27 Million USD | 93.385% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 91.17% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -64.813% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 96.171% |
| Statera Biopharma, Inc. | 21.16 Million USD | 33.353% |
| ImmunityBio, Inc. | 504.45 Million USD | 97.203% |
| Korro Bio, Inc. | 221.66 Million USD | 93.635% |
| Kineta, Inc. | 10.28 Million USD | -37.234% |
| BioVie Inc. | 25.2 Million USD | 44.03% |
| Codexis, Inc. | 136.56 Million USD | 89.668% |
| Celularity Inc. | 143.88 Million USD | 90.195% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 97.779% |
| Celcuity Inc. | 191.21 Million USD | 92.622% |
| Virax Biolabs Group Limited | 5.48 Million USD | -157.277% |
| Cibus, Inc. | 544.41 Million USD | 97.408% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 88.793% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 31.323% |
| IN8bio, Inc. | 33.7 Million USD | 58.145% |
| Kodiak Sciences Inc. | 479.37 Million USD | 97.057% |
| Annexon, Inc. | 297.67 Million USD | 95.26% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 91.845% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 89.737% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 32.792% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.528% |
| Eyenovia, Inc. | 28.77 Million USD | 50.975% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 93.88% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -95.307% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 76.842% |
| Arcellx, Inc. | 825.13 Million USD | 98.29% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 82.717% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 96.948% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 54.117% |
| Moolec Science SA | 24.05 Million USD | 41.338% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 95.451% |
| Geron Corporation | 394.07 Million USD | 96.42% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 86.128% |
| Royalty Pharma plc | 16.38 Billion USD | 99.914% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 97.629% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -101.707% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -17.308% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 93.759% |
| Humacyte, Inc. | 128.22 Million USD | 88.997% |
| Structure Therapeutics Inc. | 482.01 Million USD | 97.073% |
| 89bio, Inc. | 596.26 Million USD | 97.634% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 94.405% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -662.649% |
| Genelux Corporation | 27.89 Million USD | 49.417% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 84.219% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 93.85% |
| Notable Labs, Ltd. | 19.54 Million USD | 27.798% |
| Liquidia Corporation | 120.43 Million USD | 88.285% |
| Mustang Bio, Inc. | 17.74 Million USD | 20.477% |
| Immunovant, Inc. | 666.71 Million USD | 97.884% |
| Quantum-Si incorporated | 298.25 Million USD | 95.269% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 90.229% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 73.949% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 91.963% |
| Acasti Pharma Inc. | 73.3 Million USD | 80.752% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -209.933% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 45.977% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 98.538% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -171.854% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 38.067% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 72.659% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 92.192% |
| PepGen Inc. | 143.05 Million USD | 90.137% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 63.082% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.803% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 26.458% |
| Solid Biosciences Inc. | 164.93 Million USD | 91.446% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -140.265% |
| Immuneering Corporation | 102.58 Million USD | 86.246% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -227.46% |
| Silo Pharma, Inc. | 7.74 Million USD | -82.142% |
| Belite Bio, Inc | 94.64 Million USD | 85.092% |
| XOMA Corporation | 234.3 Million USD | 93.978% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 93.95% |
| Bionomics Limited | 27.64 Million USD | 48.971% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 96.485% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 86.862% |
| uniQure N.V. | 831.68 Million USD | 98.304% |
| Cassava Sciences, Inc. | 151.66 Million USD | 90.697% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -216.758% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 94.849% |
| Forte Biosciences, Inc. | 38.98 Million USD | 63.805% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -246.393% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 61.693% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -95.307% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -301.623% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -19.355% |
| Altimmune, Inc. | 210.64 Million USD | 93.302% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 98.186% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 86.862% |
| Compugen Ltd. | 121.33 Million USD | 88.372% |
| Peak Bio, Inc. | 2.59 Million USD | -443.403% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 91.813% |
| Benitec Biopharma Inc. | 52.21 Million USD | 72.976% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 95.873% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 59.425% |
| Zura Bio Limited | 100.84 Million USD | 86.009% |
| PolyPid Ltd. | 15.37 Million USD | 8.216% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 88.172% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 59.425% |
| Instil Bio, Inc. | 325.63 Million USD | 95.667% |
| argenx SE | 4.54 Billion USD | 99.689% |
| Immunome, Inc. | 148.54 Million USD | 90.502% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 91.006% |
| Verona Pharma plc | 308.12 Million USD | 95.421% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 83.775% |
| Shattuck Labs, Inc. | 159.56 Million USD | 91.158% |
| CervoMed Inc. | 9.97 Million USD | -41.479% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 92.513% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -23.894% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 92.136% |
| Moolec Science SA | 24.05 Million USD | 41.338% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -130.634% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 91.842% |
| AnaptysBio, Inc. | 452.38 Million USD | 96.881% |
| Design Therapeutics, Inc. | 289.64 Million USD | 95.129% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 80.626% |
| NeurAxis, Inc. | 509.49 Thousand USD | -2669.196% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -160.41% |
| Lumos Pharma, Inc. | 40.63 Million USD | 65.281% |
| Achilles Therapeutics plc | 161.45 Million USD | 91.261% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 83.775% |
| 180 Life Sciences Corp. | 5.25 Million USD | -168.259% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 79.967% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -64.813% |
| Nutriband Inc. | 7.51 Million USD | -87.691% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 94.46% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 92.921% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 81.487% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 75.639% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 97.32% |
| Palisade Bio, Inc. | 14.05 Million USD | -0.406% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 93.291% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.033% |
| Neurogene Inc. | 222.57 Million USD | 93.661% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 97.818% |
| AEON Biopharma, Inc. | 6.84 Million USD | -106.121% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 96.886% |
| Sesen Bio, Inc. | 189.17 Million USD | 92.542% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 94.81% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -2.896% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 98.192% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 94.716% |
| Athira Pharma, Inc. | 160.24 Million USD | 91.195% |
| Vaccinex, Inc. | 3.63 Million USD | -288.571% |
| HCW Biologics Inc. | 28.51 Million USD | 50.518% |
| XOMA Corporation | 234.3 Million USD | 93.978% |
| Nektar Therapeutics | 398.03 Million USD | 96.455% |
| Arvinas, Inc. | 1.3 Billion USD | 98.919% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 17.188% |
| Merus N.V. | 458.49 Million USD | 96.923% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 93.096% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 92.171% |
| Rezolute, Inc. | 132.73 Million USD | 89.371% |
| Clene Inc. | 52.34 Million USD | 73.044% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 5.46% |
| BeyondSpring Inc. | 24.8 Million USD | 43.127% |
| Synlogic, Inc. | 75.55 Million USD | 81.325% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -18.943% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -50.673% |
| Peak Bio, Inc. | 2.59 Million USD | -443.403% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 91.93% |
| Krystal Biotech, Inc. | 818.35 Million USD | 98.276% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 94.132% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 98.056% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -294.417% |
| MannKind Corporation | 475.19 Million USD | 97.031% |
| Ikena Oncology, Inc. | 192.09 Million USD | 92.655% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -5.496% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 87.893% |
| Gossamer Bio, Inc. | 311.91 Million USD | 95.477% |
| CohBar, Inc. | 16.36 Million USD | 13.789% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 59.875% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -92.878% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.237% |
| Mural Oncology plc | 301.74 Million USD | 95.324% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 54.801% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -148.38% |
| Disc Medicine, Inc. | 367.99 Million USD | 96.166% |
| Champions Oncology, Inc. | 26.13 Million USD | 46.009% |
| REGENXBIO Inc. | 573.97 Million USD | 97.542% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -420.995% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 90.861% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -16.839% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 95.851% |
| Vaxart, Inc. | 91.83 Million USD | 84.636% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 76.447% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 90.488% |
| Cellectis S.A. | 334.27 Million USD | 95.779% |
| Longeveron Inc. | 12.17 Million USD | -15.856% |
| Repare Therapeutics Inc. | 253.9 Million USD | 94.443% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.568% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 92.975% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.324% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -768.246% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 94.92% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 91.349% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 89.831% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 44.718% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.938% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 98.777% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -15.528% |
| Veru Inc. | 50.59 Million USD | 72.114% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 69.027% |
| Cingulate Inc. | 3.49 Million USD | -304.103% |
| Passage Bio, Inc. | 150.54 Million USD | 90.628% |
| Context Therapeutics Inc. | 16.06 Million USD | 12.163% |
| Exicure, Inc. | 11.58 Million USD | -21.839% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 96.248% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 91.271% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 19.248% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 95.76% |
| Nuvalent, Inc. | 732.38 Million USD | 98.074% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 5.588% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 84.245% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 0.578% |
| OmniAb, Inc. | 401.98 Million USD | 96.49% |
| Anew Medical, Inc. | 19.45 Million USD | 27.482% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 47.21% |
| Lipocine Inc. | 23 Million USD | 38.659% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 89.908% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 95.383% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 83.192% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 88.391% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -77.807% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 98.401% |
| Ocugen, Inc. | 64.54 Million USD | 78.142% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 88.671% |
| Q32 Bio Inc. | 306.11 Million USD | 95.391% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -235.29% |
| Alumis Inc. Common Stock | 89.61 Million USD | 84.255% |
| Equillium, Inc. | 50.53 Million USD | 72.078% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 81.237% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 65.816% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -729.525% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 46.027% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 78.106% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -278.55% |
| Dominari Holdings Inc. | 57.55 Million USD | 75.487% |
| Edesa Biotech, Inc. | 8.89 Million USD | -58.699% |
| vTv Therapeutics Inc. | 11.01 Million USD | -28.054% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.498% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 98.494% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 98.261% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 94.919% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 66.167% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 97.887% |
| Nkarta, Inc. | 378.88 Million USD | 96.276% |
| BioCardia, Inc. | 2.98 Million USD | -372.347% |
| Iterum Therapeutics plc | 26.25 Million USD | 46.27% |